$66.60
1.08% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US09061G1013
Symbol
BMRN

Biomarin Pharmaceutical Target price 2024 - Analyst rating & recommendation

Biomarin Pharmaceutical Classifications & Recommendation:

Buy
76%
Hold
24%

Biomarin Pharmaceutical Price Target

Target Price $96.72
Price $66.60
Potential
Number of Estimates 25
25 Analysts have issued a price target Biomarin Pharmaceutical 2025 . The average Biomarin Pharmaceutical target price is $96.72. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 29 analysts: 22 Analysts recommend Biomarin Pharmaceutical to buy, 7 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Biomarin Pharmaceutical stock has an average upside potential 2025 of . Most analysts recommend the Biomarin Pharmaceutical stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Billion $ 2.42 2.82
18.16% 16.50%
EBITDA Margin 12.35% 19.11%
125.44% 54.72%
Net Margin 6.93% 14.73%
0.70% 112.53%

25 Analysts have issued a sales forecast Biomarin Pharmaceutical 2024 . The average Biomarin Pharmaceutical sales estimate is

$2.8b
Unlock
. This is
2.61% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$2.8b 3.64%
Unlock
, the lowest is
$2.8b 1.64%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $2.4b 18.16%
2024
$2.8b 16.50%
Unlock
2025
$3.1b 9.82%
Unlock
2026
$3.4b 9.21%
Unlock
2027
$3.6b 5.16%
Unlock
2028
$3.8b 6.05%
Unlock

5 Analysts have issued an Biomarin Pharmaceutical EBITDA forecast 2024. The average Biomarin Pharmaceutical EBITDA estimate is

$539m
Unlock
. This is
9.83% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$596m 21.45%
Unlock
, the lowest is
$475m 3.15%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $299m 166.38%
2024
$539m 80.25%
Unlock
2025
$869m 61.34%
Unlock
2026
$1.1b 28.02%
Unlock
2027
$1.4b 27.10%
Unlock
2028
$1.6b 13.46%
Unlock

EBITDA Margin

2023 12.35% 125.44%
2024
19.11% 54.72%
Unlock
2025
28.07% 46.89%
Unlock
2026
32.91% 17.24%
Unlock
2027
39.78% 20.88%
Unlock
2028
42.56% 6.99%
Unlock

21 Biomarin Pharmaceutical Analysts have issued a net profit forecast 2024. The average Biomarin Pharmaceutical net profit estimate is

$415m
Unlock
. This is
31.25% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$619m 95.78%
Unlock
, the lowest is
$353m 11.45%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $168m 17.33%
2024
$415m 147.58%
Unlock
2025
$602m 45.09%
Unlock
2026
$780m 29.48%
Unlock
2027
$915m 17.32%
Unlock
2028
$1.1b 20.89%
Unlock

Net Margin

2023 6.93% 0.70%
2024
14.73% 112.53%
Unlock
2025
19.46% 32.11%
Unlock
2026
23.07% 18.55%
Unlock
2027
25.74% 11.57%
Unlock
2028
29.34% 13.99%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ 0.88 2.18
17.33% 147.73%
P/E 30.57
EV/Sales 4.38

21 Analysts have issued a Biomarin Pharmaceutical forecast for earnings per share. The average Biomarin Pharmaceutical <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$2.18
Unlock
. This is
31.33% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$3.25 95.78%
Unlock
, the lowest is
$1.85 11.45%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $0.88 17.33%
2024
$2.18 147.73%
Unlock
2025
$3.16 44.95%
Unlock
2026
$4.09 29.43%
Unlock
2027
$4.80 17.36%
Unlock
2028
$5.81 21.04%
Unlock

P/E ratio

Current 40.04 74.36%
2024
30.57 23.65%
Unlock
2025
21.07 31.08%
Unlock
2026
16.27 22.78%
Unlock
2027
13.87 14.75%
Unlock
2028
11.47 17.30%
Unlock

Based on analysts' sales estimates for 2024, the Biomarin Pharmaceutical stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.50 34.59%
2024
4.38 2.56%
Unlock
2025
3.99 8.94%
Unlock
2026
3.66 8.43%
Unlock
2027
3.48 4.91%
Unlock
2028
3.28 5.71%
Unlock

P/S ratio

Current 4.62 33.30%
2024
4.50 2.55%
Unlock
2025
4.10 8.95%
Unlock
2026
3.75 8.43%
Unlock
2027
3.57 4.91%
Unlock
2028
3.36 5.71%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today